Keros Therapeutics officially transitioned into a publicly traded corporate entity during the spring of the year 2020. The company's common stock officially commenced trading on the Nasdaq Global Market under the ticker symbol KROS on April 8, 2020, following the successful pricing of its initial public offering. Through this milestone public offering managed by prominent financial underwriters, the clinical-stage biopharmaceutical firm raised significant capital to support the ongoing clinical advancement of its proprietary protein-engineering platform and therapeutic pipeline targeting rare neuromuscular and pulmonary disorders.